Clinical response to apatinib monotherapy in advanced non ‐small cell lung cancer

ConclusionsApatinib is effective and well tolerated in patients with advanced NSCLC, even at a dosage of 500 mg qd, and might offer a new option for the treatment of such patients with brain metastases.

Source: Asia-Pacific Journal of Clinical Oncology - December 1, 2017 Category: Cancer & Oncology Authors: Jianping Xu, Xiaoyan Liu, Sheng Yang, Xiangru Zhang, Yuankai Shi Tags: ORIGINAL ARTICLE Source Type: research